Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy
Pérez-Ruiz E (1,2,3), Etxeberria I (1,2), Rodriguez-Ruiz ME (1,2,4,5), Melero I (6,2,4,5).
T-cell costimulation and coinhibition can be respectively exploited by blocking and agonist mAbs. Both strategies can be synergistically combined in mouse models.
Early clinical results from combinations of anti-PD-1 mAbs in conjunction with agonist anti-CD137 (4-1BB) mAbs show excellent safety and promising efficacy. Clin Cancer Res; 23(18); 5326-8. ©2017 AACRSee related article by Tolcher et al., p. 5349.
CITATION Clin Cancer Res. 2017 Sep 15;23(18):5326-5328. doi: 10.1158/1078-0432.CCR-17-1799. Epub 2017 Aug 8.